DexCom, Inc. (DXCM) Stake Raised by Swiss National Bank

Swiss National Bank grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 318,400 shares of the medical device company’s stock after buying an additional 10,500 shares during the period. Swiss National Bank owned 366,398.16% of DexCom worth $15,578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in DXCM. FMR LLC increased its position in DexCom by 9.9% in the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after purchasing an additional 978,898 shares during the last quarter. Janus Henderson Group PLC increased its position in DexCom by 101,699.8% in the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after purchasing an additional 6,822,023 shares during the last quarter. Vanguard Group Inc. increased its position in DexCom by 3.4% in the second quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after purchasing an additional 224,808 shares during the last quarter. BlackRock Inc. increased its position in DexCom by 5.5% in the second quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after purchasing an additional 230,542 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in DexCom by 18.2% during the second quarter. Ameriprise Financial Inc. now owns 3,948,468 shares of the medical device company’s stock worth $288,669,000 after buying an additional 607,972 shares during the period.

Several research analysts have commented on DXCM shares. TheStreet lowered shares of DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wedbush reaffirmed a “buy” rating and set a $76.00 price objective on shares of DexCom in a research note on Wednesday, October 4th. Robert W. Baird reaffirmed a “hold” rating and set a $79.00 price objective on shares of DexCom in a research note on Sunday, September 10th. Finally, Barclays PLC started coverage on shares of DexCom in a research note on Friday, September 15th. They set an “equal weight” rating and a $76.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $70.69.

In other news, EVP Andrew K. Balo sold 3,244 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $72.27, for a total transaction of $234,443.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Steven R. Altman acquired 10,000 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were bought at an average price of $49.61 per share, for a total transaction of $496,100.00. Following the acquisition, the director now owns 4,353 shares of the company’s stock, valued at $215,952.33. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 13,964 shares of company stock valued at $948,039. 1.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (DXCM) Stake Raised by Swiss National Bank” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/11/20/dexcom-inc-dxcm-stake-raised-by-swiss-national-bank.html.

Shares of DexCom, Inc. (DXCM) opened at $54.01 on Monday. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply